Stock FLUO FLUOGUIDE A/S
Add to a list
To use this feature you must be a member
Log inSign up

FluoGuide A/S

Equities

FLUO

DK0061123312

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm
Other stock markets
 10:41:57 2024-04-24 am EDT 		5-day change 1st Jan Change
48.2 SEK +9.79% Intraday chart for FluoGuide A/S +13.68% -21.24%
Mar. 20 FluoGuide A/S Approves Board Changes CI
Mar. 12 FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about FluoGuide A/S

FluoGuide A/S Approves Board Changes CI
FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc CI
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001 CI
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer CI
FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference CI
Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague CI
FluoGuide A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer CI
FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer CI
Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer CI
FluoGuide A/S Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
FluoGuide A/S Appoints Michael Thyrring Engsig as Member of the Board of Directors CI
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2022 CI
FluoGuide A/S Updates on Recruitment in Phase IIb Aggressive Brain Cancer Trial with FG001 CI
Sweden's FluoGuide Names Successor as CFO Resigns MT
FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer CI
FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer CI
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
FluoGuide Enrolls First Patient for Technology Platform Study in Head, Neck Cancer MT
FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer CI
FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply CI
FluoGuide A/S Releases Positive Interim Result of FG001-CT002 CI
FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer CI

Chart FluoGuide A/S

Chart FluoGuide A/S
More charts

Company Profile

FluoGuide A/S is a Denmark-based biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent. The Company is a provider of solutions for maximizing surgical outcome through intelligent targeting. FluoGuide develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The Company’s main product, FG001, is designed using FluoGuide’s uPAR technology platform to improve surgical precision by illuminating cancer cells intraoperatively. FluoGuide explores FG001 in three other severe cancer indications, namely lung, head & neck, meningioma and low grade glioma.
Sector
Advanced Medical Equipment & Technology
Calendar
2024-05-29 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
FLUOGUIDE A/S Stock FluoGuide A/S
-21.24% 49.47M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.78% 219B
DANAHER CORPORATION Stock Danaher Corporation
+8.24% 187B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.16% 134B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.12% 101B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.30% 62.27B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+16.21% 52.82B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-1.63% 47.49B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-1.11% 40.79B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+12.16% 39.35B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. FLUO Stock
  4. News FluoGuide A/S
  5. FluoGuide Enrolls First Patient for Technology Platform Study in Head, Neck Cancer